Vitamin D prophylaxis in persons with epilepsy?

Area of Science:

• Neurology
• Endocrinology
• Public Health

Background:

• Osteoporosis prevention guidelines are limited in the general population, with vitamin D supplementation commonly recommended.
• Persons with epilepsy (PWE) face complex factors increasing vitamin D deficiency risk.
• No international guidelines exist for monitoring bone health in PWE.

Purpose of the Study:

• To review evidence on vitamin D deficiency risk factors in PWE.
• To identify high-risk groups for bone health issues within the PWE population.
• To propose optimal bone health monitoring strategies for PWE.

Main Methods:

• Narrative review of existing evidence.
• Analysis of risk factors for vitamin D deficiency and impaired bone health.
• Identification of specific high-risk subgroups within the PWE population.

Main Results:

• Anti-seizure medication (ASM) use, particularly enzyme-inducing ASMs and valproic acid, is a key risk factor for poor bone health and vitamin D deficiency.
• High-risk groups include individuals with disabilities, institutionalized patients, postmenopausal women, and those on multiple medications.
• A monitoring scheme involving lab tests, bone density, risk management, and vitamin D supplementation is suggested.

Conclusions:

• Regular vitamin D measurement is cost-effective for PWE. High-risk PWE benefit from combined vitamin D and bone densitometry monitoring.
• Continuous vitamin D supplementation for all PWE is not supported by current evidence.
• Children with epilepsy require age-appropriate vitamin D intake, with additional monitoring and supplementation for high-risk cases.